RDY

15.55

0.13% 0.02

Dopo l'orario di chiusura: 15.51 -0.04 -0.26%

Dr Reddys Laboratories Ltd Adr (RDY)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Perché RDY Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$15.53

Aprire:

$15.53

Volume 24 ore:

1.47M

Relative Volume:

0.77

Capitalizzazione di mercato:

$12.98B

Reddito:

$3.85B

Utile/perdita netta:

$667.93M

Rapporto P/E:

23.67

EPS:

0.657

Flusso di cassa netto:

$142.30M

1 W Prestazione:

+5.64%

1M Prestazione:

+15.10%

6M Prestazione:

+6.73%

1 anno Prestazione:

+10.52%

Intervallo 1D:

$15.44

$15.58

Intervallo di 1 settimana:

$14.61

$15.71

Portata 52W:

$12.26

$16.89

Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile

Nome

Dr Reddys Laboratories Ltd Adr

Settore

Healthcare (1171)

Industria

Drug Manufacturers - Specialty & Generic (1)

Telefono

Indirizzo

Dipendente

27,048

Cinguettio

@drreddys

Prossima data di guadagno

2025-01-23

Ultimi documenti SEC

RDY's Discussions on Twitter

Confronta RDY con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RDY Dr Reddys Laboratories Ltd Adr	15.55	12.27B	3.85B	667.93M	142.30M	0.657
HLN Haleon Plc Adr	11.07	50.98B	14.35B	1.85B	0	0.4023
ZTS Zoetis Inc	170.16	74.41B	9.29B	2.52B	2.28B	5.57
RDHL Redhill Biopharma Ltd Adr	1.99	4.03M	35.75M	11.57M	-26.25M	-3.8069
TAK Takeda Pharmaceutical Co Adr	14.96	46.23B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	17.77	20.10B	16.54B	-1.64B	749.00M	-1.45

Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-19	Downgrade	Nomura	Buy → Neutral
2024-01-11	Downgrade	Jefferies	Buy → Underperform
2023-08-29	Downgrade	HSBC Securities	Buy → Hold
2023-05-18	Downgrade	Bernstein	Outperform → Mkt Perform
2023-03-17	Aggiornamento	BofA Securities	Neutral → Buy
2023-01-30	Iniziato	JP Morgan	Underweight
2022-11-14	Downgrade	Credit Suisse	Neutral → Underperform
2022-01-03	Ripresa	BofA Securities	Neutral
2021-07-27	Downgrade	Credit Suisse	Outperform → Neutral
2021-02-02	Aggiornamento	Barclays	Equal Weight → Overweight
2020-09-18	Aggiornamento	BofA Securities	Neutral → Buy
2020-09-18	Aggiornamento	Investec	Sell → Hold
2020-01-28	Downgrade	CLSA	Buy → Outperform
2020-01-27	Downgrade	CLSA	Buy → Outperform
2020-01-09	Aggiornamento	Citigroup	Sell → Buy
2019-11-04	Downgrade	BofA/Merrill	Buy → Neutral
2019-09-04	Aggiornamento	Credit Suisse	Underperform → Outperform
2019-07-01	Aggiornamento	Macquarie	Neutral → Outperform
2019-06-20	Iniziato	Deutsche Bank	Hold
2019-06-11	Iniziato	Barclays	Equal Weight
2019-05-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2019-02-19	Aggiornamento	CLSA	Outperform → Buy
2019-01-17	Downgrade	Citigroup	Neutral → Sell
2017-09-21	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2017-08-31	Aggiornamento	CLSA	Underperform → Outperform
2017-07-28	Downgrade	CLSA	Underperform → Sell
2016-07-27	Downgrade	HSBC Securities	Hold → Reduce
2016-07-27	Downgrade	Jefferies	Hold → Underperform
2016-02-10	Aggiornamento	Credit Agricole	Underperform → Buy
2015-11-10	Downgrade	Citigroup	Buy → Neutral

Mostra tutto

Dr Reddys Laboratories Ltd Adr Borsa (RDY) Ultime notizie

Jun 05, 2025

HSBC Upgrades Dr. Reddy’s Laboratories Limited (RDY) to Buy from Hold - Insider Monkey

Jun 05, 2025

Dr. Reddy’s stock rises on biosimilar collaboration with Alvotech By Investing.com - Investing.com Nigeria

Jun 05, 2025

Dr. Reddy’s stock rises on biosimilar collaboration with Alvotech - Investing.com Australia

Jun 05, 2025

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab) - GlobeNewswire Inc.

Jun 05, 2025

HSBC upgrades Dr. Reddy’s stock rating citing semaglutide prospects - Investing.com Australia

Jun 05, 2025

Jun 03, 2025

LLY Stock Quote Price and Forecast - CNN

Jun 03, 2025

May 27, 2025

Asian Equities Gain In US Markets' Positive Start - Finimize

May 27, 2025

May 13, 2025

Indian ADRs Surge in US Markets as Wall Street soars after US-China trade talks - Moneycontrol

May 13, 2025

May 12, 2025

Shares To Buy For Short-term: Analysts recommend 5 largecap, 2 midcap stocks; Britannia, Dr Reddy's, TCS on the list - Zee Business

May 12, 2025

May 10, 2025

Asian Equities Climb Despite Weekly Losses - Finimize

May 10, 2025

May 09, 2025

Dr. Reddy’s Earnings: Year-End Numbers Look Solid as Demand and Prescription Trends Remain Resilient - Morningstar

May 09, 2025

Dr. Reddy’s Laboratories Grants Stock Options to Employees in May 2025 - TipRanks

May 09, 2025

Insider’s View: Deciphering Six Flags Entertainment Corp (FUN)’s Financial Health Through Ratios - DWinneX

May 09, 2025

Balance Sheet Breakdown: Astrazeneca plc ADR (AZN)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX

May 09, 2025

Ratio Examination: Dr. Reddy’s Laboratories Ltd. ADR (RDY)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX

May 09, 2025

Metric Deep Dive: Understanding Phio Pharmaceuticals Corp (PHIO) Through its Ratios - DWinneX

May 09, 2025

Financial Analysis: Spotify Technology S.A (SPOT)’s Ratios Unveil Key Insights - DWinneX

May 09, 2025

5 Indian ADRs crash up to 14% amid rising India-Pakistan military conflict - Trade Brains

May 09, 2025

May 08, 2025

Indian Markets Set for Bloody Friday as Gift Nifty Signals Sharp Gap-Down Open Amid Escalating India-Pak Tensions - outlookbusiness.com

May 08, 2025

Indian ADRs slump as India-Pakistan conflict sees escalation - Moneycontrol

May 08, 2025

Gift Nifty, India ADRs see sharp sell-off following escalation in India-Pakistan conflict - Moneycontrol

May 08, 2025

May 06, 2025